ISRCTN35425744已完成未知
Safety and intake effect of EPs® 7630 (an extract of the roots of Pelargonium sidoides): a randomised controlled trial
Dr. Willmar Schwabe GmbH & Co. KG (Germany)0 个研究点目标入组 798 人开始时间: 2014年12月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 798
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adult male or female participant (at least 18 years old)
- •2. Participant provided a written informed consent in accordance with the legal requirements
- •3. Participant with willingness and ability to comply with all procedures of the clinical trial and be available for the duration of the study
- •4. Participant is of good physical and mental condition
- •5. Participant experienced at least 2 colds per year in the last 12 months
排除标准
- •1. Chronic respiratory tract or lung disease (e.g. chronic bronchitis, COPD, bronchial asthma, cystic fibrosis, active pulmonary tuberculosis, lung cancer)
- •2. History of heart, renal, liver, neuromuscular disease and/or immunosuppression
- •3. Known allergic bronchial asthma
- •4. Known or suspected congenital anomalies of heart, kidney, liver, or mental disabilities
- •5. Participant with concomitant medications that might impair the interpretation of trial results (e.g. herbal medications for common cold other than the investigational product, or pain relief medications other than Paracetamol or Ibuprofen)
- •6. Women of child-bearing potential with no adequate and effective contraception (MHRA, 2010):
- •6.1. Established use of oral, injected or implanted hormonal methods of contraception
- •6.2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
- •6.3. Barrier methods of contraception: Condom and/or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
- •6.4. Sexual abstinence
- •6.5. Vasectomised partner
- •7. Female participant who is pregnant, lactating or planning pregnancy during the course of the clinical trial
- •8. Participant with cold symptoms at inclusion
- •9. Current intake of antimicrobial and/or antiviral medication for any reason
- •10. Participant with known or suspected history of alcohol or drug abuse
- •11. Heavy smoking (more than 10 cigarettes per day)
- •12. Psychiatric disorders which may influence the results of the trial, epilepsy, or suicide attempts
- •13. Planned surgical intervention during the trial
- •(14)Known gastrointestinal disorders with uncertain absorption of orally administered medication (e.g. partial or total gastrectomy, enterectomy, inflammatory bowel disease, celiac disease, symptomatic lactose intolerance, disbacteriosis) or associated with diarrhoea
- •15. Known or suspected hypersensitivity to the active substance or to any of the excipients of the investigational product
- •16. Known clinically relevant laboratory abnormalities
- •17. Participant with increased tendency to bleed, especially nasal or gingival bleeding
- •18. Previous (within the last 3 months prior to visit 1) or concomitant treatment with coagulation-inhibiting drugs such as warfarin
- •19. Participation in a further clinical trial at the same time or within the last 4 weeks prior to inclusion into the present study
- •20. Previous randomisation in the present clinical study
- •21. Irresponsible subjects or those unable to understand nature, meaning and consequences of the trial
研究者
相似试验
进行中（未招募）
1 期
Safety and intake effect of EPs®7630 (an extract from the roots of Pelargonium sidoides)common coldMedDRA version: 16.1 Level: LLT Classification code 10010106 Term: Common cold System Organ Class: 100000004862EUCTR2013-004977-28-GBDr. Willmar Schwabe GmbH & Co. KG798
已完成
3 期
Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides)Common ColdNCT02174653Dr. Willmar Schwabe GmbH & Co. KG720
进行中（未招募）
不适用
Efficacy and tolerability of EPs® 7630 solution in patients (>=18 years old) with Acute Rhinopharyngitis (ARP)Adult patients suffering from acute Rhinopharyngitis.EUCTR2007-005579-33-BGDr. Willmar Schwabe GmbH &Co. KG
进行中（未招募）
不适用
Efficacy and tolerability of EPs 7630 solution in patients (> = 18 years old) with Acute Rhinopharyngitis (ARP)Adult patients are suffering at an acute Rhinopharyngitis. They will take 10 days 3x 30 drops per day of the investigational product and they will have 4 Visits.EUCTR2007-004923-39-DEDr. Willmar Schwabe GmbH & Co. KG
已完成
4 期
To gain further information about the safety of EPs® 7630 film-coated tablets (Kaloba 20 mg Filmtabletten) in adult subjects (greater than or equal to 18 years old) suffering from common cold symptomsCommon coldRespiratoryISRCTN65790556Dr. Willmar Schwabe GmbH & Co. KG (Germany)120